Hinge Health Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw revenue and profitability far exceed expectations, driven by strong demand, AI-enabled efficiency, and rapid adoption of new offerings like Migraine Care. Guidance for 2026 was raised significantly, reflecting robust pipeline growth and expanding client base.
Fiscal Year 2025
-
Delivered record 2025 results with 51% revenue growth, 31% free cash flow margin, and strong client expansion. Guidance for 2026 projects 25% revenue growth and continued profitability, with investments in AI and Hinge Select positioning for long-term market leadership.
-
Q3 revenue grew 53% year-over-year to $154M, with gross margin at 83% and operating margin at 20%. Strong client growth, robust free cash flow, and AI-driven efficiency led to raised full-year guidance and continued investment in R&D and new products.
-
Q2 2025 saw 55% year-over-year revenue growth to $139M, with strong operating and free cash flow margins. Guidance for 2025 was raised, driven by higher eligible lives, improved yields, and product innovation, including the launch of Hinge Select.